Wellthy Therapeutics is a digital therapeutics (DTx) company that helps healthcare stakeholders to improve patient outcomes. Its digital therapeutics platform works to manage and improve complex clinical conditions, and works closely with pharma, med device, life insurers, health insurers and healthcare systems to achieve the same.

Wellthy Therapeutics’ platform develops and deploys digital therapeutic candidates for commercialisation in indications across cardiology, nephrology and diabetes, and is live in two countries. The company has 20+ publications showcasing its real-world evidence. For more information, please visit www.wellthytherapeutics.com.
Abhishek Shah is the Co-Founder of Wellthy Therapeutics, a digital therapeutics company that uses artificial intelligence (AI) and patient centric design to improve patient outcomes for all stakeholders in chronic disease management. Abhishek Shah co-founded Wellthy with the mission to transform chronic care in India by driving digital therapeutics that will improve health literacy, facilitate behavior change and help reverse and control diabetes.

Abhishek Shah comes with more than a decade of healthcare experience, having previously co-led an early stage fund as a venture capitalist, been an entrepreneur in residence, and held leadership positions in his healthcare family businesses. He holds a B.S. in Chemical and Biomolecular Engineering from Georgia Tech and an MBA from the Indian School of Business (ISB).

Link to his LinkedIn profile: https://www.linkedin.com/in/abhinshah/
Prayat Shah
Co-Founder & VP - Enterprise Partnerships

Prayat believes that improved patient outcomes lead to better business outcomes. He leads enterprise sales to insurance, pharmaceutical and med device companies. Previously, he worked with KPMG and PWC. He has an MBA from the Indian School of Business and a Bachelors in Science from Nanyang Technical University, Singapore.

Link to his LinkedIn profile: https://www.linkedin.com/in/prayat-shah-3b992429/